The US Food and Drug Administration’s latest report to Congress on opening a regulatory pathway for using cannabidiols in products other than drugs makes clear that an additional $5m to support the work that House appropriators propose for the agency’s fiscal 2021 budget is needed.
While the FDA’s second report in 2020 to Congress on its oversight of CBD manufacturing and marketing includes results from some studies of whether products are mislabeled or adulterated,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?